#HOjournalclub Transcript
Healthcare social media transcript of the #HOjournalclub hashtag.
– ().
See #HOjournalclub Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | HOJournalClub @HOJournalClub It's that time! 👋 Thanks everyone for joining our chat tonight! Please start introducing yourselves. We'll get started with Q1 in a few minutes. Don't forget to reply to main posts and include #HOJournalClub in your posts! #SickleCell #hematology #scd https://t.co/4KN1lcnuxT |
 | Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub Hello! I’m Tiffany Lucas at @UCSF working as a pediatric hematologist oncologist (shout out to #phodocs) with a focus in hematology and #MedEd as the fellowship program director! So excited to join you all today to discuss this paper. #HOJournalClub |
 | Devika Das, MD, MSHQS @DevikaDasMD @HOJournalClub Hi !! Devika Das - adult med Onc from Birmingham AL joining in #hojournalclub #scd #hematology |
| HOJournalClub @HOJournalClub @DrTiffanyL @UCSF Thanks for being with us! #HOJournalClub |
 | Shonali Midha, M.D. @ShoMidha @HOJournalClub Hi! Shonali Midha @MoffittNews 2nd-year fellow and #ASH19 neighbor #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @ShoMidha @HOJournalClub @MoffittNews So great to have a fellow join us! #HOJournalClub |
| HOJournalClub @HOJournalClub @amarkelkar @UFMedicine Thanks for joining us! #HOJournalClub |
| HOJournalClub @HOJournalClub @dr_jdavid @UFHealthCancer Welcome! We're glad you're here! #HOJournalClub |
| HOJournalClub @HOJournalClub While people are joining, let's kick things off with Q1: please describe the study design and methods. What were the proposed endpoints? Who was included? (Don't forget to reply below using A1 etc.) #HOJournalClub #SickleCell #pho #phodocs #hematology #ASH19 https://t.co/PQugGK9J22 |
 | Mansour Gergi MD @Mansourgergi @HOJournalClub A1 RCT phase 3 1:1:1 between 1500 mg 900 mg and placebo patients from age 12-65 with sickle cell and varients Primary endpoint increase to 1g/dl of hb at 24 weeks #HOjournalclub |
| Devika Das, MD, MSHQS @DevikaDasMD @HOJournalClub A1 #HOjournalclub #scd https://t.co/l35Kl3pOXc |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub A1/ This is a phase 3 randomized control trial — they randomized to two dose levels of voxelotor or placebo in a 1:1:1 fashion in patients with sickle cell disease. #HOJournalClub |
| Shonali Midha, M.D. @ShoMidha @HOJournalClub A1: Int'l, multi-center double-blind RCT of voxelotor 900mg vs 1500mg vs placebo in 1:1:1 ratio in 274 #scd patients (mostly homozygous Hgb S or S/Beta-thal) . PE was a change in hgb > 1 g/dl by week 24, 2dary endpoints included change in iBili, %ret, abs rec, LDH #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub A1: The patients were age 12 and up, had SS, SC or Sbeta null disease with 2/3rds of the study population on hydroxyurea at baseline. #HOJournalClub |
| Devika Das, MD, MSHQS @DevikaDasMD @HOJournalClub A1 #HOjournalclub #scd https://t.co/AYzbBJyVfC |
 | Natasha Dhawan, MD @NatashaDhawanMD @HOJournalClub Hi all! I'm Natasha, palliative care fellow and newly matched heme/onc fellow @DartmouthHitch! Unfortunately, I'm on call, so I'll have to be observer this time. #HOJournalclub |
| HOJournalClub @HOJournalClub @Mansourgergi What did you think about the study population? Anything you would have considered doing differently? #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub A1: I think it was great to include patients on hydroxyurea (HU) as it is the first FDA approved drug for pediatric patients with #sickle cell — it’s in the 2014 NHLBI report as a recommendation for infants >9 months of age to be offered HU. #HOJournalClub |
 | Martina Murphy, MD @DrMMurphy @HOJournalClub A1 (more of an additional question): what do we think about these endpoints? Clinical relevance? Patient-reported outcomes are always important, IMO. What about the others? #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub (Fact: L-glutamine was approved as the second for peds patients in 2017). #HOJournalClub |
| HOJournalClub @HOJournalClub @NatashaDhawanMD @DartmouthHitch Thanks for coming by to check in! Hope call is smooth. 👌 #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @DrMMurphy @HOJournalClub Exactly right, what do people think? #HOJournalClub |
| HOJournalClub @HOJournalClub Excellent background intel! #HOJournalClub |
| HOJournalClub @HOJournalClub RT @DrMMurphy: @HOJournalClub A1 (more of an additional question): @HOJournalClub A1 (more of an additional question): what do we think about these endpoints? Clinical relevance? Patient-reported outcomes are always important, IMO. What about the others? #HOJournalClub |
| Shonali Midha, M.D. @ShoMidha @DrMMurphy @HOJournalClub Thats my main issue with this study, where as L-glutamine and p-selectin trials evaluated incidence sickle cell crises, there is limited data that increased hgb/decreased hemolysis to this extent is clinically relevant (as evidenced by 2dary outcomes here) #HOJournalClub |
 | Jonathan Berry @jlberrymd Hi all! Jonathan tweeting from @BIDMC_IM in Boston. I'm a PGY-3 and just found out that I'll be starting H/O fellowship here at BI in July! #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub A1: (or extra Q) As diff drugs are being developed for sickle cell that have different potential effects, there are varied primary study outcomes. Is it possible this lab-based outcomes was chosen because it could be reached first — over a clinical outcome? #HOJournalClub |
| HOJournalClub @HOJournalClub @ShoMidha @DrMMurphy Great points. What do you think motivated these decisions @DrTiffanyL ? #HOJournalClub |
| Mansour Gergi MD @Mansourgergi @DrMMurphy @HOJournalClub A1 I would have preferred having Vaso-occlusive crisis or need for transfusions as a primary endpoint as they’re more clinically relevant for practice and patient outcomes #HOJournalClub |
| Jonathan Berry @jlberrymd A1 While they addressed in the conclusion that the increased hgb has correlated w/ clinical outcomes I wonder if it's the most patient-centered endpoint #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub @ShoMidha @DrMMurphy That's always hard to say -- clinical trial design is complicated, always great to have these Phase 3 RCT's (our "gold standard") but it makes for complicated statistical endpoints at times when considering patient numbers and more. #HOJournalClub |
| HOJournalClub @HOJournalClub With background in mind, and awareness about the ending selected, let's consider the results. Q2: What were study results? Treatment benefits? Were the trial endpoints met? Primary/Secondary? #HOJournalClub #SickleCell #hematology #PHOdocs https://t.co/IfWgy0vkeD |
| Tiffany (Lin) Lucas @DrTiffanyL @jlberrymd Exactly - we should bring up the secondary outcomes and what they saw there .. I think we'll get to that soon ;) #HOJournalClub |
| HOJournalClub @HOJournalClub RT @DrTiffanyL: @HOJournalClub @ShoMidha @DrMMurphy That's always hard to say -- clinical trial design is complicated, always great to have these Phase 3 RCT's (our "gold standard") but it makes for complicated statistical endpoints at times when considering patient numbers and more. #HOJournalClub |
| HOJournalClub @HOJournalClub RT @Mansourgergi: @DrMMurphy @HOJournalClub A1 I would have preferred having Vaso-occlusive crisis or need for transfusions as a primary endpoint as they’re more clinically relevant for practice and patient outcomes #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @Mansourgergi @DrMMurphy @HOJournalClub I think many feel the same. Of note, I looked back and the HU NEJM paper from 1995 reported on 'frequency of painful crises' as their primary outcome and same for the NEJM reported L-Glutamine trial in 2018. #HOJournalClub |
| HOJournalClub @HOJournalClub @DrTiffanyL @Mansourgergi @DrMMurphy Interesting. Did that require significantly expanded study size/duration? #HOJournalClub |
| Jonathan Berry @jlberrymd @DevikaDasMD @HOJournalClub The waterfall plots give a nice visual of the fact that (1) there did seem to be a significant change in the endpoint and (2) it appears that it may be dose-related (although I don't think that met significance) #HOJournalClub |
| Shonali Midha, M.D. @ShoMidha @HOJournalClub A2: Voxelotor 1500mg met PE with stat signif increase in Hgb (1.1 g/dl in ITT) compared to placebo (-0.1). Similar though not signif increase with 900mg dose. Higher dose with signif decrease in iBili and %retic, though not abs retic, LDH, or vaso-occl crises #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub A2: Also of note, the percentage of patients in each participant group who received transfusions was statistically the same (33% in the 1500 mg, 32% in the 900 mg, and 25% in the placebo group). #HOJournalClub |
| Mansour Gergi MD @Mansourgergi @HOJournalClub @DrTiffanyL @DrMMurphy Thats what they are planing to do based on their conclusion and I agree we might see a statistically significant difference in hey so occlusive crisis as there was trend towards showing some difference #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub A2: Their other secondary outcome was annual rate of vaso-occlusive crises. This trended towards decreased rates in the higher voxelotor dose groups but was not significant — with a stronger trend in patients that came in with more than two crises in the past year. #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub A2: This was their primary outcome! #HOJournalClub #scd https://t.co/YnSdBlqpuI |
| HOJournalClub @HOJournalClub You guys are on 🔥. Keep the comments coming! Continuing to Q3: What were the major adverse events? What do you think of the benefits vs harms? Anything you find surprising? ⚖️ #HOJournalClub #SickleCell https://t.co/OntR1vOcrx |
| Tiffany (Lin) Lucas @DrTiffanyL @DevikaDasMD @Mansourgergi @HOJournalClub @DrMMurphy Totally -- I'm hoping there were more outcomes not reported that will come with time as they continue to follow this cohort. #HOJournalClub |
| HOJournalClub @HOJournalClub @DrTiffanyL Nice! No such thing as #HOJournalClub mistakes! 👍🏻 |
| Mansour Gergi MD @Mansourgergi @HOJournalClub A3 headache and diarrhea or the most common, most of these side effects were great one or two so basically it was pretty safe with no major difference in side effects with placebo #HOJournalClub |
| HOJournalClub @HOJournalClub Oooh here's hoping! @ASH_hematology we'll be keeping a lookout #SickleCell #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub A3/ The adverse events (AE) noted during this study are reported in Table 3 of the study. Number of AEs across the board (placebo and treatment groups) were in the 89-94% range and it does not appear to have been statistically significant. #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @arkhaki @DevikaDasMD @Mansourgergi @HOJournalClub @DrMMurphy Thanks for joining! #HOJournalClub |
| Devika Das, MD, MSHQS @DevikaDasMD @HOJournalClub A3 no fatal SAE in the treatment arms but the % of grade 3 is concerning ( while weighing in risk/ benefit ) #HOJournalclub https://t.co/Umk5wBEZay |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub A3: the highest reported percentage of AEs was 26% of the 1500 mg voxelotor group reporting headache with other reports of diarrhea, nausea, arthralgia, abdominal pain, fatigue, and rash — but these were also commonly reported in the placebo group. #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub A3: FOOD FOR THOUGHT. I just wanted to point out that there were still fatal adverse events during the trial — all adjudicated as unrelated to the trial drug/placebo — but we are still trying to prevent death in these patients from complications of their disease! #HOJournalClub |
 | Ali Khaki @arkhaki @Mansourgergi @HOJournalClub @DrTiffanyL @DrMMurphy While that is good that we should learn more, I think the primary endpoint of a phase 3 clinical trial should be clinically meaningful rather than an invalidated surrogate #scd #HOJournalClub |
| Shonali Midha, M.D. @ShoMidha @HOJournalClub A3: Similar to L-glutamine, no sig increase in AE attributed to voxelotor; similar rates of of H/A, diarrhea, pain crises, mortality. The slight trend to decreased crises in 1500mg group is difficult to interpret and would need longer evaluation #HOJournalClub |
| HOJournalClub @HOJournalClub @DevikaDasMD The rates of AEs in placebo group is telling. #SickleCell hurts. #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub A3: For the trainees: Note the adverse events related to sickle cell disease that were excluded (see footnote under Table 3 if you are just learning about the seriousness of #sicklecell) #ConquerSCD #MedEd #HOJournalClub |
| Devika Das, MD, MSHQS @DevikaDasMD RT @DrTiffanyL: @HOJournalClub A3: For the trainees: @HOJournalClub A3: For the trainees: Note the adverse events related to sickle cell disease that were excluded (see footnote under Table 3 if you are just learning about the seriousness of #sicklecell) #ConquerSCD #MedEd #HOJournalClub |
| HOJournalClub @HOJournalClub Yes! Excellent point to emphasize for trainees-- don't forget the extra details in footnotes & appendices when reviewing publications. #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @ShoMidha @HOJournalClub Yup, totally agree! #HOJournalClub |
 | ASH19 VIP @SimonASH15 #ASH2019 #ASH19 👇👇 |
| Shonali Midha, M.D. @ShoMidha @DrTiffanyL @HOJournalClub Interesting that they exluded "sickle cell anemia with crisis" but did comment on decreased "acute anemia episodes" with drop of Hgb >/= 2 g/dl. Wouldn't this often overlap clinically? @DrTiffanyL #HOJournalClub |
| HOJournalClub @HOJournalClub @arkhaki @Mansourgergi @DrTiffanyL @DrMMurphy This is a valid concern, having more relevant #PRO or clinical impact measures could have helped here. #HOJournalClub #SickleCell |
| HOJournalClub @HOJournalClub @arkhaki @UWMedicine @SeattleCCA @fredhutch Better late than never! Happy to have you join us! #HOJournalClub |
| HOJournalClub @HOJournalClub Excellent discussion so far everyone! Now for Q4: How applicable are these results to your own patients? Will these results affect your practice? Why/why not? #HOJournalClub #SickleCell https://t.co/RX0TBpKZHn |
| HOJournalClub @HOJournalClub RT @SimonASH15: #ASH2019 #ASH19 👇👇 |
| Tiffany (Lin) Lucas @DrTiffanyL @ShoMidha @HOJournalClub Definitely. I wonder how these are separately defined. Maybe related to other causes of anemia in sickle cell disease patients such as parvovirus or ?random blood loss. #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub Looking forward to everyone's thoughts on this!! #HOJournalClub |
| HOJournalClub @HOJournalClub RT @DrTiffanyL: @HOJournalClub Looking forward to everyone's thoughts on this!! #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub A4: How do we decide which patient gets offered what combination? Does it depend on your patients’ clinical scenario? How does this impact the idea of drug adherence? #HOJournalClub |
| Shonali Midha, M.D. @ShoMidha @HOJournalClub A4: Def exciting to have gone from 2 to 4 FDA-approved treatments for #scd within a couple months, however given no head-to-head eval of L-glutamine vs p-selectin vs voxelotor and lack of clear clinical benefit here, I would likely choose the former choices #HOJournalClub |
| Ali Khaki @arkhaki @DrTiffanyL @HOJournalClub It’s interesting that the approval was accelerated approval despite a phar 3 study. Goes to the point we have discussed of needing better evidence of (clinically meaningful) efficacy. What is the follow-up trial fda is requiring? #HOJournalClub #SCD |
| HOJournalClub @HOJournalClub A4: Is cost coverage equivalent? How does #financialtoxicity come into play? #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @ShoMidha @HOJournalClub Thoughts about the length of time on these drugs to reach an effect? HU data was about 6 months after they started, L-glutamine at week 48, voxelotor's endpoint (non-clin) at week 24. #HOJournalClub |
| Shonali Midha, M.D. @ShoMidha @DrTiffanyL @HOJournalClub Actually had a patient in clinic today, 28y/o F stable on Hydrea, however concerned of conception planning and if need to hold hydrea, would consider L-glutamine or evaluate preg safety categories of these newer agents... #HOJournalClub |
| HOJournalClub @HOJournalClub RT @ShoMidha: @DrTiffanyL @HOJournalClub Actually had a patient in clinic today, 28y/o F stable on Hydrea, however concerned of conception planning and if need to hold hydrea, would consider L-glutamine or evaluate preg safety categories of these newer agents... #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @arkhaki @HOJournalClub Good question -- anyone here with insider information about this? #HOJournalClub #scd #voxelotor |
| ASH19 VIP @SimonASH15 RT @ShoMidha: @HOJournalClub Hi! Shonali Midha @MoffittNews 2nd-year fellow and #ASH19 neighbor #HOJournalClub |
| HOJournalClub @HOJournalClub @DrTiffanyL @arkhaki . @tmprowell any thoughts on an @FDAOncology heme contact who could comment? #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub Super important point here. Where is the #healthequity and how will it be applied. Especially as we think of other potentially curative options for #sicklecell and who has access to those. #HOJournalClub |
| HOJournalClub @HOJournalClub In the interest of time, here's our final question--Q5: what do you see as "next steps" from here? What further questions does this raise? #HOJournalClub #SickleCell https://t.co/FbvfhAPSE9 |
| HOJournalClub @HOJournalClub RT @DrTiffanyL: @HOJournalClub Super important point here. Where is the #healthequity and how will it be applied. Especially as we think of other potentially curative options for #sicklecell and who has access to those. #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @arkhaki @HOJournalClub As of Dec 5, 2019 -- I would put my patients on hydroxyurea as per the NHLBI 2014 guidelines and consider the addition of L-glutamine in those with continued increase in #sicklecellcrises. I think the idea of lack of safety information on combos worries me a bit! #HOJournalClub |
| Ali Khaki @arkhaki @ShoMidha @DrTiffanyL @HOJournalClub Any evidence (even preclinical) to suggest this is safe in pregnancy? That would make me nervous and I think I would lean to L-glutamine if paucity of data #SCD #HOJournalClub |
| HOJournalClub @HOJournalClub @ShoMidha @DrTiffanyL Pretty cool that you're able to consider these questions in real-time! #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @arkhaki @ShoMidha @HOJournalClub Preclinical data in pregnancy will be hard to find -- nothing published yet. Hopefully we get more data as people are using in pregnant patients. @ShoMidha - great point re: conception planning and great job on having those convos with your patients! #HOJournalClub |
| Shonali Midha, M.D. @ShoMidha @HOJournalClub A5: Having more treatment options to mitigate m&m was much-needed in an area that affects millions, would like to see true clinical benefit with longer eval. However, I'm most excited to see what potentially curative options gene therapy will bring in the future #HOJournalClub |
| HOJournalClub @HOJournalClub Expert summary opinion here! 👇 #HOJournalClub #sicklecell #PHOdocs |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub A5/ This is such an exciting time to be a hematologist in caring for patients’ with #sicklecell. While these new drugs are being developed/tested, there have also been advances in gene tx, not to mention the last decades of advances in stem cell transplant for #scd #HOJournalClub |
| Ali Khaki @arkhaki @ShoMidha @HOJournalClub I question the utility of treatment options when clinical benefit has not been confirmed. The most efficient way to get answers on safety and efficacy is on trial not in the real world. Otherwise we potentially cause much more harm without proven benefit. #SCD #HOJournalClub |
| Ali Khaki @arkhaki @ShoMidha @HOJournalClub Look forward to future studies hopefully with meaningful endpoints. I’m off thanks to all for a great discussion #HOJournalClub #SCD |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub A5/ (2 of 2).. advancing access to potentially curative therapies and continuing to work on the safety and efficacy of current and future curative options, educating providers that provide pain control in these patients, and.. this list could go on and on. #HOJournalClub |
| HOJournalClub @HOJournalClub @DrTiffanyL It is exciting that attention and research $ is being funneled into such an impactful disease. On the verge of a brighter future for #SCD? 🙏 #SickleCell #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub Yes for sure -- SO much work to do not just on the science but the world we live in today as that also impacts our #SickleCell patients. #HOJournalClub |
| Ali Khaki @arkhaki @ShoMidha @HOJournalClub I should qualify that safety sometimes is discovered in real world because of power considerations but true efficacy should be confirmed in a well designed trial #scd #HOJournalClub |
| Jonathan Berry @jlberrymd Sorry I disappeared; I'm on call and had to step away but have been enjoying the discussion! #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @arkhaki @ShoMidha @HOJournalClub Safety is totally clinically relevant for our patients - so don't back down on asking for that when we can get it from a well-designed trial! #HOJournalClub |
| HOJournalClub @HOJournalClub Thank you so much for for the great discussion tonight everyone! This concludes our #SickleCell #HOJournalClub! Extra huge thanks to @DrTiffanyL for the valuable insights! 🙌 Feel free to keep the discussion going! #hematology #scd #oncmeded #PHO #PHOdocs |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub (2 of 2) in the original Oksenberg from British J of Hematology 2016 it describes these molecules are preferentially stabilizing the R relaxed state (i.e. oxyHb) in patients with SS RBCs. How does it affect those with hemoglobin F? #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @HOJournalClub Tag a colleague in sickle cell so we can get connected here before the ASH meeting! See you all there #ASH19. Check out the voxelotor and crizanlizumab poster presentations on Saturday and Sunday! And find me to continue this convo in person! #HOJournalClub |
| HOJournalClub @HOJournalClub We'd love your feedback! All participants please take a quick survey to let us know how we're doing! 👇 https://t.co/AJvbmG0eOw #HOJournalClub #oncmeded #hematology #oncology #PHOdocs #hemeoncfellows https://t.co/O8W9I48OGe |
| Tiffany (Lin) Lucas @DrTiffanyL RT @HOJournalClub: We'd love your feedback! All participants please take a quick survey to let us know how we're doing! 👇 https://t.co/AJvbmG0eOw #HOJournalClub #oncmeded #hematology #oncology #PHOdocs #hemeoncfellows https://t.co/O8W9I48OGe |
 | Liza Henry McDonald @DocLHenry Nice! Real time #SickleCell community building! #HOJournalClub |
| Martina Murphy, MD @DrMMurphy Thanks so much to all our early adopters! If you've every participated (either actively or just followed along silently) we'd love if you'd take 30 seconds to fill out this brief survey. We want to make this the best educational experience possible! #HOJournalClub |
| HOJournalClub @HOJournalClub @sicklecelldoc @DrTiffanyL @Mansourgergi @DevikaDasMD Interesting observation @sicklecelldoc, would've thought #SickleCell studies would always include some #Pediatrics population to be relevant. #HOJournalClub |
| HOJournalClub @HOJournalClub RT @DrMMurphy: Thanks so much to all our early adopters! If you've every participated (either actively or just followed along silently) we'd love if you'd take 30 seconds to fill out this brief survey. We want to make this the best educational experience possible! #HOJournalClub |
| Tiffany (Lin) Lucas @DrTiffanyL @sicklecelldoc @HOJournalClub Yup! totally right -- looking at Table 1 -- had a number of patients with Sickle beta+ thalassemia (actually -- more in the 1500 mg Voxelotor group... should highlight that as well)#HOJournalClub |
 | Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @DrMMurphy: Friends - join us TONIGHT for a special, pre-#ASH19 edition of #HOJournalClub. @DrTiffanyL will join us for a robust discussion of this recent advance in the care of patients with #SickleCell. See you there! @DevikaDasMD @DocLHenry @ASH_hematology @ahmaruroojzaidi @sicklecelldoc |
#HOjournalclub content from Twitter.